Skip to main content

Incyte Corporation (INCY) Stock

Incyte Corporation Stock Details, Movements and Public Alerts

Stock Details

Incyte Corporation (INCY), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $93.00. Over the past 52 weeks, it has ranged between $53.56 and $112.29. This places the current price at 82.8% of its 52-week high and 73.6% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 34.67, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $101.52 by 8.39%. Similarly, it is above its 200-day moving average of $89.14 by 4.33%. The MACD histogram is -0.66, indicating bearish momentum (MACD Line: -2.34, Signal Line: -1.69). The International Securities Identification Number (ISIN) for this stock is US45337C1027. There are currently 3 active alerts set for INCY by users.

52-Week Range

$112.29 - $53.56

-17.18% from high · +73.64% from low

Avg Daily Volume

1,658,051

20-day average

100-day avg: 2,125,286

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

14.51

Below market average

Forward P/E

10.75

Earnings expected to grow

Price to Book

3.57

EV/EBITDA

10.41

EPS (TTM)

$6.41

Price to Sales

3.60

Beta

0.84

Less volatile than market

Q:How is INCY valued relative to its earnings and growth?
Incyte Corporation trades at a P/E ratio of 14.51, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 10.75 is lower than the current P/E, indicating analysts expect earnings to grow over the next year.
Q:What is INCY's risk profile compared to the market?
With a beta of 0.84, Incyte Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.57 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

25.03%

Operating Margin

25.57%

EBITDA

$1.44B

Return on Equity

29.87%

Return on Assets

13.57%

Revenue Growth (YoY)

27.80%

Earnings Growth (YoY)

43.60%

Q:How profitable and efficient is INCY's business model?
Incyte Corporation achieves a profit margin of 25.03%, meaning it retains $25.03 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 25.57% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 29.87% and ROA at 13.57%, the company generates strong returns on invested capital.
Q:What are INCY's recent growth trends?
Incyte Corporation's revenue grew by 27.80% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 43.60% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$18.5B

Revenue (TTM)

$5.14B

Revenue/Share (TTM)

$26.34

Shares Outstanding

199.01M

Book Value/Share

$26.04

Asset Type

EQUITY

Q:What is INCY's market capitalization and position?
Incyte Corporation has a market capitalization of $18.5B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 199.01M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does INCY's price compare to its book value?
Incyte Corporation's book value per share is $26.04, while the current stock price is $93.00, resulting in a price-to-book (P/B) ratio of 3.57. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$107.59

15.69% upside potential

Analyst Recommendations

Strong Buy

2

Buy

9

Hold

12

Sell

2

Strong Sell

0

Q:How reliable are analyst predictions for INCY?
25 analysts cover INCY with 44% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $107.59 implies 15.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on INCY?
Current analyst recommendations:2 Strong Buy, 9 Buy, 12 Hold, 2 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 17, 2026, 02:10 AM

Technical Indicators

RSI (14-day)

34.67

Neutral

50-Day Moving Average

$101.52

-8.39% below MA-50

200-Day Moving Average

$89.14

4.33% above MA-200

MACD Line

-2.34

MACD Signal

-1.69

MACD Histogram

-0.66

Bearish

Q:What does INCY's RSI value tell investors?
The RSI (Relative Strength Index) for INCY is currently 34.67, indicating the stock is showing bearish momentum (30-40 range). Selling pressure is evident but not extreme. This often occurs during pullbacks in uptrends or early stages of downtrends. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret INCY's MACD and moving average crossovers?
MACD analysis shows the MACD line at -2.34 below the signal line at -1.69, with histogram at -0.66. This bearish crossover indicates downward pressure. The 50-day MA ($101.52) is above the 200-day MA ($89.14), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 17, 2026, 12:32 AM

Active Alerts

Alert Condition
Price rises above
Threshold
$112.00
Created
Mar 2, 2026, 04:30 AM
Alert Condition
Price rises above
Threshold
$125.00
Created
Jan 15, 2026, 01:59 AM
Alert Condition
Earnings Announcement
Threshold
3 days
Created
Jan 15, 2026, 01:52 AM

Stay Ahead of the Market with Incyte Corporation Alerts

Set up price alerts for Incyte Corporation and get notified instantly when the price hits your target. Never miss an important price movement again.